SCHEMBL4256317

SCHEMBL4256317

CCCC(=O)N1CC[C@H](O)[C@@H]1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
EPHX1 P07099 2/20 0.35
EPHX2 P34913 2/20 0.35
ACE P12821 1/20 0.34
FFAR3 O14843 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
GNAI3 P08754 2/20 0.32
GNAO1 P09471 2/20 0.32
GNAI1 P63096 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256319 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4248756 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL28220251 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4258808 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4248760 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4259086 1.00 CHRNB2 (0.36) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL6516411 0.87 GNAI3 (0.48) GNAI3GNAO1GNAI1MEN1KMT2A
SCHEMBL396910 0.87 GNAI3 (0.48) GNAI3GNAO1GNAI1MEN1KMT2A
SCHEMBL16781379 0.87 GNAI3 (0.48) GNAI3GNAO1GNAI1MEN1KMT2A
SCHEMBL4252620 0.85 TSHR (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111632095-A Antibacterial vagina tightening and contracting composition and application thereof 上海赫依美容美体有限公司 2020-09-08 CN disclosed
US-8338404-B2 Composition and method for reducing allergen KYOWA HAKKO BIO CO., LTD. (JP) 2012-12-25 US disclosed
US-20090069403-A1 COMPOSITION AND METHOD FOR REDUCING ALLERGEN KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-03-12 US disclosed
US-20080188546-A1 Preventive or therapeutic agents for decubitus TAKEDA TOSHIAKI 2008-08-07 US disclosed
US-20080102042-A1 Dentifrices containing N-acyl derivative of hydroxyproline; periodontal disease KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-01 US disclosed
US-20070293559-A1 Orally Administered Agent For Preventing Or Improving Dry Station Of Skin KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-12-20 US disclosed
CN-101027050-A Oral preparation for preventing or improving dry skin KYOWA HAKKO KOGYO KK (JP) 2007-08-29 CN disclosed
EP-1795191-A1 ORAL PHARMACEUTICAL FOR DRY SKIN PREVENTION OR REMEDY KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-06-13 EP disclosed
US-20060034781-A1 PERORAL PREPARATION FOR PREVENTION OR TREATMENT OF ATOPIC DERMATATIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-02-16 US disclosed
US-20060035957-A1 Preventive or remedy for bedsore KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-02-16 US disclosed
EP-1559425-A1 PERORAL PREPARATION FOR PREVENTION OF OR TREATMENT FOR ATOPIC DERMATITIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-08-03 EP disclosed
EP-1547594-A1 PREVENTIVE OR REMEDY FOR BEDSORE KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-06-29 EP disclosed
US-20030185864-A1 Preventives or remedies for atopic dermatitis KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-02 US disclosed
EP-1304323-A1 PREVENTIVES OR REMEDIES FOR ATOPIC DERMATITIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069403-A1 COMPOSITION AND METHOD FOR REDUCING ALLERGEN TSLP, CARM1, CMA1 CHRNB2 1728/4885CHRNA3 1822/4885CHRNA4 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.